drugset / Trial / NCT00402025

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

NCT00402025

Phase 1 Completed 17 enrolled BioVex Limited
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety of injections of talimogene laherparepvec into patients with pancreatic cancer that cannot be removed by surgery. The study will also test whether the injections are effective in treating the tumor.

Timeline

Start
2006-11
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified 4 ml Other